814263-30-4

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(Boc-amino)-5-cyanopyridine is used as a building block for the synthesis of pharmaceutical compounds. Its unique structure and functional groups make it a valuable component in creating complex organic molecules with potential medicinal properties.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(Boc-amino)-5-cyanopyridine serves as a key intermediate for the creation of various organic materials. Its compatibility with different functional groups allows for the development of a wide range of chemical products.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 55338-73-3 5-amino-2-cyanopyridine 

Downstream Products

• 858599-23-2 tert-butyl (6-acetylpyridin-3-yl)carbamate 

Relevant academic research and scientific papers

SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrrolo[l,2-a]pyrimi dines and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrrolo[1,2-a]pyrimidines compounds described herein include substituted 2,4-dimethyl-N-phenylpyrrolo[l,2-a]pyrimidine-8-carboxamide compounds and variants thereof.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

PYRIDINONE AND PYRIMIDINONE DERIVATIVES AS FACTOR XIA INHIBITORS

The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.